Comparison of the efficacy of Dexmedetomidine versus Ketamine as an adjunct to Ropivacaine for Scalp nerve block during Awake craniotomy surgery- A Randomised Controlled Trial Authors: Muhammed M Faiz, Ashwini Reddy, Ankur Luthra, Rajeev Chauhan, Shyam Charan Meena, Sushant Sahoo Published: 2026 ABSTRACT AbstractBackgroundScalp nerve block (SNB) is an established technique for effective analgesia during awake craniotomy, but its analgesic duration is limited when local anesthetics are used alone. Adjuvants such as dexmedetomidine and ketamine may enhance block efficacy, though direct comparative evidence remains limited.MethodsThis prospective trial randomized forty-six adult patients undergoing elective awake craniotomy to receive SNB with 0.5% ropivacaine with dexmedetomidine 1 µg/kg (Group RD, n = 23) or ketamine 0.5 mg/kg (Group RK, n = 23). The primary outcome was the time to request the first rescue analgesia. Secondary outcomes included onset of sensory blockade, postoperative pain scores, rescue analgesic consumption, hemodynamic variables, respiratory depression, psychosis, and time to discharge from the postoperative ward.ResultsThe time to first rescue analgesia was significantly longer in Group RK compared with Group RD (18.67 [17.08–19.00] vs. 14.67 [12.92–15.08] hours; P = 0.001). Group RK demonstrated significantly lower postoperative pain scores at 6,10, and 16 h postoperatively (P < 0.004) and reduced consumption of rescue analgesia (P < 0.001). The onset of sensory blockade was comparable with a higher incidence of respiratory depression in Group RD (P = 0.02). Group RK showed higher intraoperative heart rate and mean arterial pressure, though values remained within clinically acceptable limits.ConclusionKetamine (0.5 mg/kg) as an adjuvant to ropivacaine for SNB in awake craniotomy provides longer postoperative analgesia and reduced rescue analgesic requirements compared with dexmedetomidine, with a lower incidence of respiratory depression. Dexmedetomidine offers superior hemodynamic attenuation to noxious stimuli. Larger multicenter studies are warranted to establish optimal adjuvant selection.Clinical trial registrationClinical Trials Registry-India (CTRI): CTRI/2024/01/061259, https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=OTY2NDQ=&Enc=&userName= Date of registration: 09/01/2024Date of enrolment of first patient: 15/01/2024Principal Investigator: Dr Ankur LuthraSupplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12871-026-04006-4.Keywords: Scalp nerve block, Awake craniotomy, Dexmedetomidine, Ketamine, Adjuvant Introduction Anaesthesia for craniotomy in an awake patient necessitates a precise balance between adequate sedation and analgesia to guarantee patient comfort while preserving spontaneous ventilation and facilitating neurological assessment [1]. Inadequate control of post-craniotomy pain may trigger agitation, hypertension, nausea and vomiting, which can subsequently precipitate a rise in intracranial pressure, and negatively impact neurological outcomes [2]. Although opioids are routinely administered to attenuate these hemodynamic responses and provide analgesia, their use is associated with several undesirable effects, including respiratory depression, interference with postoperative neurological assessment, and prolonged recovery [3]. Consequently, opioid-sparing analgesic strategies have become integral components of enhanced recovery after surgery (ERAS) pathways for awake craniotomy [4, 5]. Scalp nerve block (SNB) effectively attenuates the hemodynamic response to noxious stimuli, reduces perioperative opioid use, and enhances patient comfort during awake craniotomy, thereby facilitating faster recovery and shorter hospital stay [6, 7]. However, when performed with local anaesthetics alone, the analgesic effect of SNB is often transient, with maximal benefit largely confined to the early postoperative period [8]. Hence the use of adjuvants is essential to enhance block efficacy, accelerate onset, and prolong the duration of analgesia without significant adverse effects. Dexmedetomidine, an α₂-adrenergic receptor agonist, exhibits analgesic, sedative and anxiolytic effects. Its addition to local anaesthetic solutions in SNB has been shown to prolong sensory blockade and delay the requirement for rescue analgesia [9, 10]. However, the high vascularity of the scalp increases the potential for unpredictable systemic absorption, leading to excessive sedation and hemodynamic instability. Ketamine has been demonstrated to decrease the intensity and duration of pain post craniotomy and opioid consumption when used as an adjuvant in SNB [11, 12]. Importantly, ketamine provides effective sedation while maintaining respiratory drive and hemodynamic stability. However, its clinical utility may be limited by psychotropic adverse effects, such as hallucinations, which are undesirable in the neurosurgical population [13]. A literature review reveals a dearth of trials directly comparing adjuvants like dexmedetomidine and ketamine in SNB in patients undergoing awake craniotomy. Hence, we carried out this study to evaluate the efficacy of ketamine and dexmedetomidine as adjuvants to 0.5% ropivacaine in prolonging the duration of postoperative analgesia provided by SNBs. Materials and methods Study setting This prospective, randomized trial was carried out at a tertiary-care centre (January–December 2024) following Declaration of Helsinki guidelines, with prior approval by the Institutional Ethics Committee (IEC/INT/2023/MD-1323) of the Post Graduate Institute of Medical Education and Research, Chandigarh (Chairperson Prof Praveen Kumar) on 20/11/2023 and CTRI registration (CTRI/2024/01/061259) on 09/01/2024 before enrolment of patients. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The trial was designed, conducted, and reported in accordance with the Consolidated Standards of Reporting Trials guidelines. Participants and randomization Adults aged 18–65 years belonging to ASA I and II posted for awake craniotomy for brain tumour excision were enrolled after obtaining written informed consent. Patients with a history of prior craniotomy, BMI > 35 kg/m2, or any allergy to study drugs were excluded from the study. Patients with a history of psychiatric disorders, chronic pain disorder/ opioid abuse, coagulopathy, hepatic or renal impairment, and cardiopulmonary disorders were not included. Patients were randomly assigned to two groups using a computer-generated random number table, and allocation concealment was achieved through the sealed opaque envelope technique, accessible only to the primary investigator responsible for study drug preparation. Patients in Group RD received SNB with 20 mL of 0.5% Ropivacaine and 1 µg/kg of dexmedetomidine. The dose of dexmedetomidine was chosen based on prior literature establishing the safety and efficacy of perineural dexmedetomidine [9, 10, 13]. Patients in Group RK received SNB with 20 ml of 0.5% Ropivacaine + 0.5 mg/kg ketamine. We selected 0.5 mg/kg, as supported by evidence from recent studies with comparable dose ranges [14]. In addition, pilot cases conducted at our institution demonstrated that ketamine in the range of 0.3–0.5 mg/kg provided adequate analgesia and patient comfort during scalp block without significant adverse effects. Based on these observations, 0.5 mg/kg was selected as an optimal balance between efficacy and safety. The preparation of drugs was done in identical syringes, and the patient, anaesthesiologist administering the block, and the investigator assessing the postoperative outcomes were not aware of the study drug. Study procedure A thorough preanaesthetic examination was done prior to the surgery. A multidisciplinary team, consisting of a neurosurgeon, a neuroanesthesiologist, and technicians, was assembled prior to each case to discuss the procedural steps and the patient’s neurological testing. On the day of awake craniotomy, after ensuring appropriate fasting, the patient was taken to the operating theatre, where standard ASA monitoring was established and baseline SpO₂, heart rate (HR), and mean arterial pressure (MAP) were recorded. All patients received an intravenous bolus of fentanyl (1 µg/kg) and ondansetron (0.1 mg/kg). This was followed by initiation of an intravenous infusion of dexmedetomidine at 0.5 µg/kg/h to maintain a Richmond Agitation Sedation Scale (RASS) score of 1–2. The patient was then positioned comfortably, and oxygen was delivered via nasal cannula at 3–4 L/min. Bilateral SNBs were performed using the method by Pinosky et al. [15] followed by radial arterial cannulation. The dexmedetomidine infusion was continued until 20 min before the neurological assessment by the surgeon and restarted after the completion of the assessment, and continued until the last skin suture was placed. A fentanyl bolus (0.25 µg/kg) was administered whenever the patient reported discomfort (NRS > 4). The incidence of SNB failure requiring conversion to general anesthesia was documented. Assessment of primary outcome The interval from the onset of sensory blockade to the first postoperative administration of a rescue analgesic agent was recorded. Post-craniotomy pain was assessed using NRS pain scores every 2 h till 24 h and the rescue analgesia was administered if NRS ≥ 4. Between assessment points, if the patient complained of pain with NRS being ≥ 4, the rescue analgesia was administered. Assessment of secondary outcomes The time of onset of sensory block was assessed using pinprick sensation at every 1-minute interval following the administration of SNB until the sensation was lost. The total consumption of the rescue analgesic agent was also recorded. The first line agent was intravenous paracetamol 1 gm. If the NRS ≥ 4 despite intravenous paracetamol 1 gm administered after 30 min, the second-line agent used was intravenous ketorolac 30 mg. The total 24 h rescue analgesic agent consumption was recorded. Intraoperatively, hemodynamic and respiratory parameters, namely the HR, MAP, Saturation and Respiratory Rate (RR), were recorded at 10-minute intervals from the point of administration of SNB till completion of the procedure and every 15 min till 2 h postoperatively. Bradycardia (HR < 40/min) was treated with atropine 15 µg/kg. Hypotension was defined as SBP < 90 mm Hg sustained for 2 min and was treated by a fluid bolus of 300 ml followed by Mephentermine 3 mg/dose. Respiratory depression was defined as RR < 8 breaths/ min, and the number of episodes was recorded. A Short Orientation Memory Concentration (SOMC) Test for cognition was assessed at 30 min postoperatively for evaluation of psychosis [16]. PONV was also assessed at 2-hourly intervals postoperatively using the 4-point PONV scale. PACU discharge time was defined as the time taken to attain a Modified Aldrete score of ≥ 9. Statistical analysis Sample size estimation was performed using PASS software, with an alpha error of 5% and a study power of 80%, based on data from a recent study by Vallapu et al. [17] which reported a median pain-free duration of 12 h (IQR: 8–16) with dexmedetomidine as an adjuvant to bupivacaine in scalp nerve block (p < 0.0001) among 50 patients. Assuming a mean pain-free duration of 18 h for scalp nerve block using ketamine as an adjuvant to 0.5% ropivacaine, and considering a clinically acceptable difference of 6 h between groups, the required sample size was calculated to be 21 patients per group. After accounting for a 10% attrition rate, 23 patients were included in each group. Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS; IBM Corp., Chicago, IL, USA; version 22). The normality of data distribution was checked using the Shapiro–Wilk test. Continuous variables with normal distribution were compared using paired or unpaired t-tests, and non-normally distributed data were compared using the Mann–Whitney U test. Categorical variables association was analysed using the Chi-square test or Fisher’s exact test, as appropriate. P < 0.05 was considered statistically significant. Postoperative pain scores were analysed using repeated measures ANOVA with time as the within-subject factor and group as the between-subject factor. Greenhouse–Geisser correction was applied where sphericity was violated. To control for type I error due to multiple comparisons across 12 postoperative time points, Bonferroni correction was applied. Accordingly, the level of statistical significance was adjusted to P < 0.004 for NRS scores. Results A total of 50 patients posted for elective awake craniotomy surgery were assessed for eligibility. Surgery was deferred in two patients due to uncontrolled hypertension, and 2 patients had active upper respiratory tract infection and were thus excluded. The remaining 46 patients were randomly divided into 2 groups of 23 each (Fig. 1). Demographic parameters, including the distribution of comorbidities and ASA physical status, were comparable across groups (Table 1). Study flow chart demonstrating subject recruitment, randomization, and analysis, CONSORT Diagram Table 1Demographic characteristics of the study populationSl No.VariableGroup RD(n = 23)Group RK(n = 23)P value1.Age,43.48 ± 8.7243.78 ± 9.300.912.Sex, (M/F)16(69.6%)/7(30.4%)12 (52.2%)/11 (47.8%)3.Weight74.00 ± 10.2970.61 ± 9.660.254.BMI (kg/m2)24.96 ± 1.4824.26 ± 1.620.135.ASA physical status19 (82.6%)/4(17.4%)18 (78.3%)/5(21.7%)16.ComorbiditiesHypertension8 (38%)9(39%)0.98Diabetes Mellitus4(17%)3(13%)Hypothyroid2(8%)1(4%)Data presented as mean ± standard deviation, n (%) or numberASA American Society of Anesthesiologists, BMI Body Mass Index*P < 0.05 is considered significant Demographic characteristics of the study population Data presented as mean ± standard deviation, n (%) or number ASA American Society of Anesthesiologists, BMI Body Mass Index *P < 0.05 is considered significant Primary outcome The time to administration of first rescue analgesia was significantly longer in Group RK (18.67 [17.08-19] v/s 14.67 [12.92–15.08], P = 0.001) as compared to Group RD, Fig. 2A. A Figure depicting the time to administration of first rescue analgesia, and B depicting the postoperative pain scores Secondary outcomes The sensory block onset was relatively slower in Group RD (5 [4,6] vs. 4 [4,6], P = 0.906) compared to Group RK, as shown in Table 2. The consumption of first-line rescue analgesia, paracetamol, was greater in Group RD (3[3,3] v/s 2[2,3], P = 0.001) in comparison to Group RK. However, the consumption of the second-line rescue analgesic agent ketorolac was comparable, as shown in Table 2. Assessment of postoperative pain revealed significantly lower NRS scores at 6 h (P = 0.004) and 10 h (P = 0.002) in Group RK compared with Group RD after Bonferroni correction for multiple comparisons (Fig. 2B). In contrast, Group RD demonstrated significantly lower pain scores at 14 h (P < 0.001) compared with Group RK. Although statistically significant differences were observed at additional time points (2, 8, 14, 18, and 20 h) prior to adjustment, these differences did not remain significant following Bonferroni correction. Overall, pain scores were lower in Group RK during the early postoperative period up to 12 h, whereas Group RD showed comparatively lower pain scores between 12 and 24 h (Supplementary Digital Content 1). There was a significant effect of time on pain scores (F(6.15, 270.71) = 34.286, p < 0.001), Table 3. Importantly, a significant group × time interaction was observed (F(6.15, 270.71) = 8.130, p < 0.001), indicating that pain trajectories differed between the groups over the postoperative period. However, the overall group effect was not significant (F(1, 44) = 0.029, p = 0.866), suggesting comparable mean pain scores when averaged across all time points, Table 3. Table 2Assessment of primary and secondary outcomes among the two groupsSl No.OutcomeGroup RD(n = 23)Group RK(n = 23)Difference (95% CI)P value1.Time to request of first rescue analgesic agent (Hours)14.67 [12.92–15.08]18.67 [17.08-19]4.00 (2.50 to 4.67) < 0.001* 2.Onset of sensory blockade (mins)4 [4–6]5 [4–6]0.00 (0.00 to 1.00)0.913.Consumption of first line rescue analgesia, paracetamol (g)3 [3–3]2 [2–2]-1.00 (-1.00 to -1.00) < 0.001* 4.Consumption of second line rescue analgesia, Ketorolac (mg)60 [30–60]60 [37.5–60]0.00 (-30.00 to 30.00)0.835.Duration of surgery (mins)180 [170–195]180 [170–190]0.00 (-10.00 to 10.00)0.676.Incidence of Respiratory depression9 (39.1%)2 (8.7%)30.4% (5.6% to 51.5%) 0.03* 7.Complications, n(%)Hypotension6 (26.1%)2 (8.7%)17.4% (-5.2% to 38.7%)0.24Psychosis0 (0.0%)2 (8.7%)-8.7% (-26.8% to 6.9%)0.48PONV3 (13.0%)6 (26.1%)-13.0% (-35.1% to 10.4%)0.458.Time to discharge from PACU13.91 ±3.3616.96 ± 4.46-3.04 (-5.39 to -0.69) 0.02* Data presented as mean ± standard deviation, Median [Interquartile range], n (%) or numberPONV Postoperative nausea and vomiting, PACU Postoperative Care Unit*P < 0.05 is considered significant (in bold letters) Assessment of primary and secondary outcomes among the two groups Data presented as mean ± standard deviation, Median [Interquartile range], n (%) or number PONV Postoperative nausea and vomiting, PACU Postoperative Care Unit *P < 0.05 is considered significant (in bold letters) Table 3Analysis of the postoperative pain scoresSourcedf (corrected)F valueP-valueTime (within-subject effect)6.15, 270.7134.286 < 0.001* Group (between-subject effect)1, 440.0290.866Time × Group interaction6.15, 270.718.130 < 0.001* Values are reported using Greenhouse–Geisser correction due to violation of sphericity (Mauchly’s test p < 0.001; ε = 0.513) Analysis of the postoperative pain scores Values are reported using Greenhouse–Geisser correction due to violation of sphericity (Mauchly’s test p < 0.001; ε = 0.513) Analysis of haemodynamics revealed a higher intraoperative HR in Group RK at 50, 60, and 70 min compared with Group RD. The intraoperative MAP was also greater at 50, 60, 70, 130, and 140 min in Group RK compared to Group RD (Fig. 3). A greater incidence of respiratory depression was seen in Group RD (39.1%) as compared to Group RK (8.7%). The frequency of side effects like hypotension, psychosis, and postoperative nausea and vomiting was comparable among the groups (Table 2). Line diagram depicting the trends of heart rate (HR) and mean arterial blood pressure (MAP) in both groups post-study drug administration Recovery profiles also differed, with Group RD showing a shorter time to discharge from PACU than Group RK (Table 2). Discussion Scalp nerve blocks (SNBs) play a pivotal role in anaesthetic management during craniotomy in an awake patient by ensuring adequate analgesia, minimising opioid consumption, and attenuating hemodynamic responses to noxious surgical stimuli. Nevertheless, when performed using local anaesthetic agents alone, the analgesic effect of SNBs is often short-lived, even in the presence of vasoconstrictors. The use of adjuvants not only improves the quality but also prolongs the duration of the SNB. In the present study, perineural ketamine demonstrated superior postoperative analgesic efficacy compared with perineural dexmedetomidine, as reflected by a delayed requirement for first rescue analgesia, lower pain scores, and lower consumption of rescue analgesic agents. Our findings align with Kaushal et al., who showed that the addition of ketamine (2 mg/kg) to bupivacaine in SNB significantly prolonged the time to first rescue analgesia (~ 8 h postoperatively) compared to local anaesthetic alone (1 h). This was accompanied by lower postoperative pain scores [11]. Similarly, Kadian et al. also reported that ketamine (2 mg/kg) as an adjuvant to SNB significantly prolonged the time to first rescue analgesic (12 h) in comparison with the use of plain local anaesthetic agents (3 h), along with reduced postoperative opioid consumption and lower pain scores [12]. In the present study, a lower dose of ketamine (0.5 mg/kg) was used with ropivacaine, taking into consideration the awake nature of the surgical procedure and the need for a fully conscious, cooperative patient without psychotropic adverse effects. Despite the reduced dose, comparable analgesic efficacy was observed. This finding may be attributable to the scalp’s high vascularity facilitating enhanced local drug absorption, thereby achieving effective analgesia at lower doses in comparison to other anatomical sites [18]. The relative potency of ketamine in combination with different local anaesthetics, however, remains insufficiently evaluated. Ketamine exerts its analgesic effects through multiple central and peripheral mechanisms, including interactions with NMDA, γ-aminobutyric acid, opioid, sigma, and monoaminergic receptors, as well as modulation of peripheral nerve ion channels. By preventing central sensitisation, ketamine plays a crucial role in the prevention of both acute and chronic pain. Additionally, its anti-inflammatory properties are particularly advantageous in the setting of surgical tissue injury. Ketamine also demonstrates synergism with local anaesthetics through sodium channel blockade and enhances the binding affinity to plasma proteins, potentially prolonging the duration of SNB [19, 20]. It also suppresses excitatory neurotransmission and lowers the activation threshold of sensory nerves, hastening the onset of sensory block. Previous studies evaluating the role of dexmedetomidine in SNB have demonstrated that the addition of dexmedetomidine (1 µg kg⁻¹) led to a significantly longer time to first rescue analgesia compared with plain local anaesthetic [17]. Furthermore, a recent meta-analysis found that perineural dexmedetomidine in SNB extended the time to first rescue analgesia by approximately 215 min and was associated with reduced intraoperative fentanyl consumption when compared with local anaesthetic alone [13]. However, direct head-to-head comparisons of these adjuvants in the context of SNB remain limited in the existing literature. While we found that ketamine provides better quality of postoperative analgesia, reflected by lower pain scores in the first 12 h post-surgery in Group RK, the relatively lower pain scores in Group RD from 12 to 24 h can be attributed to greater consumption of rescue analgesic agents. Dexmedetomidine also facilitates an earlier onset of sensory blockade through α₂-adrenergic receptor–mediated hyperpolarisation of neuronal membranes, along with sodium channel blockade [19–21]. These findings are consistent with those of Kaygusuz et al., who reported a significantly faster onset of sensory blockade with dexmedetomidine (1 µg kg⁻¹ ) as an adjunct to levobupivacaine compared with placebo (7.75 ± 2.22 min) [22]. The rapid onset observed in the present study (approximately 4 min) may be attributed to anatomical differences in nerve composition, as the scalp predominantly contains small-diameter, unmyelinated C fibres, in contrast to the thicker Aδ fibres of the brachial plexus. The incidence of respiratory depression was greater in Group RD when compared with Group RK which may be attributed to the ability of ketamine to preserve respiratory drive. In the present study, intravenous fentanyl bolus was administered for intraoperative sedation along with intermittent boluses (0.25 mcg/kg) for rescue. The combined sedative effects of dexmedetomidine and fentanyl may have contributed to the increased frequency of depression of respiration in Group RD. Despite this, intraoperative oxygen saturation remained comparable between the two groups at all measured time points. Perineural dexmedetomidine provided more effective blunting of hemodynamic responses to noxious stimuli during craniotomy as reflected by lower HR and MAP values at 50, 60, 70, 130, and 140 min when compared to perineural ketamine. This difference is likely attributable to the sympathomimetic effects of ketamine following systemic absorption, when compared to the sympatholytic properties of dexmedetomidine. These findings are supported by a recent meta-analysis, which reported that the addition of dexmedetomidine to SNB lowered HR and MAP during periods of intense sympathetic stimulation during craniotomy [13]. Such hemodynamic stability may be particularly advantageous in high-risk neurosurgical populations, including patients with intracranial aneurysms or arteriovenous malformations. The observed elevations in hemodynamics in our study occurred approximately 50–70 min after incision, coinciding with skin incision and burr hole creation, which are associated with intense nociceptive stimulation. Despite these differences, the hemodynamic changes were not clinically significant and remained within 25% of baseline values. Intraoperative opioid consumption was lower in Group RK as compared to Group RD. Excessive opioid use is associated with undesirable effects, including excessive sedation, respiratory depression, interference with postoperative neurological assessment, prolonged recovery, and an increased frequency of PONV [3]. Consequently, opioid-free or opioid-sparing analgesic strategies constitute a key element of enhanced recovery after surgery protocols in awake craniotomy [4]. Evaluation of the adverse-effect profile of both adjuvants is essential. Ketamine is known to be associated with neuropsychiatric effects; however, several studies have demonstrated that perineural ketamine results in a lower incidence of such adverse effects compared with systemic administration [23]. In the present study, two patients in Group RK exhibited SOMC < 20, indicating transient cognitive impairment. Dexmedetomidine, on the other hand, is commonly linked with bradycardia and hemodynamic fluctuations. In our study, the incidence of hypotension or bradycardia was not clinically significant. Although recovery time was longer in the perineural ketamine group, the difference between the two groups did not reach clinical significance. This study is subject to many limitations. It is a single-centre study with a modest sample size, limiting the generalizability of the results. The use of intravenous dexmedetomidine for sedation in both groups could potentially confound the effect of dexmedetomidine when used as an adjuvant in the scalp block. The use of alternative sedative regimes (e.g., propofol) could have avoided this overlap. The assessment of serum cortisol as a marker of stress and objective monitors of analgesia, like the Analgesia Nociception Index could have led to a more comprehensive evaluation of the physiological response to pain. Including a plain local anaesthetic control group would have allowed for a clearer determination of the true incremental benefit of the adjuvants. Future well-designed studies are warranted to clarify the mechanism and also the optimal perineural dose. Conclusion The use of ketamine (0.5 mg/kg) as an adjuvant to 0.5% ropivacaine for SNB in awake craniotomy provided a longer duration of postoperative analgesia as demonstrated by a longer time to administration of first rescue analgesia, lower pain scores and lower requirement of rescue analgesic agent postoperatively as compared to perineural dexmedetomidine(1 µg/kg). While the incidence of respiratory depression was lower with perineural ketamine, it was associated with a higher HR and MAP, along with a relatively longer recovery time, when compared to perineural dexmedetomidine. Larger multicentre studies are needed to conclusively establish the safety, efficacy, and optimal perineural doses of ketamine and dexmedetomidine in SNB. Supplementary information Supplementary Material 1. Acknowledgements Nil Prior Presentation ESRA 2025 at Oslo, Norway, as an E-poster. The abstract was published under the Abstracts Section (P201) as Comparison of the efficacy of dexmedetomidine versus ketamine as an adjunct to ropivacaine for scalp block during awake craniotomy surgery – a clinical comparative study in Regional Anesthesia & Pain Medicine 50 (Suppl 1), A274-275. Authors' contributions Study conception and design: AL, MF. Acquisition, analysis and interpretation of data: MF, SS, RC, SCM. Draft manuscript preparation: AR, AL. Critical revision of the manuscript for important intellectual content: AL, SCM, RC. All authors reviewed the results and approved the final version of the manuscript. This manuscript has been read and approved by all the authors, the requirements for authorship asstated earlier in this document have been met, and each author believes that the manuscriptrepresents honest work if that information is not provided in another form. Funding None. Data availability The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Institutional Ethics Committee (IEC/INT/2023/MD-1323) of the Post Graduate Institute of Medical Education and Research, Chandigarh (Chairperson Prof Praveen Kumar) on 20/11/2023. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Consent to participate Written informed consent has been obtained from all the study participants. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.